Freenome Completes SPAC Merger and Debuts on Nasdaq

Health
Health
Merger / DESPAC
Merger / DESPAC

Show Chart?

Load external content from TradingView!

*You can change or withdraw your consent at any time in the footer under Cookies.

Freenome Completes Business Combination and Debuts on Nasdaq

Brisbane, CA, USA Freenome Holdings, Inc. (Nasdaq: FRNM) has officially announced the completion of its business combination with Perceptive Capital Solutions Corp. The newly combined company, operating under the name Freenome, Inc., is set to commence trading on the Nasdaq Capital Market under the ticker symbol FRNM.

The company, which specializes in blood-based early cancer detection, enters the public market with significant capital to accelerate its growth strategy and clinical development. The transaction provides the company with approximately $310 million in gross proceeds, comprising funds from the former trust account of Perceptive Capital Solutions Corp. and a successful $240 million private placement (PIPE).

... Read on — Members only

About Freenome Holdings, Inc.

Freenome is an early cancer detection company developing blood-based tests to detect cancer when it is most treatable. The company recognizes that no single technology can identify every cancer due to the disease’s inherent heterogeneity. Freenome’s approach combines a multiomics platform that analyzes multiple signals in the blood with artificial intelligence and machine learning to tune into cancer’s subtlest clues, even at the earliest stages of the disease.

View Company Details

More FRNM News

SPAC IPO Calendar
SPAC IPO Events
Scroll to Top